Facebook
Messenger
Twitter
LinkedIn
Email
Print
Monoclonal Antibodies: Update on COVID-19 Experimental Therapy
Share this:
Current experimental treatments for COVID-19 focus on two targets: the virus or the immune system. On the immune system side, the number of experimental treatments is growing. The vast majority are called monoclonal antibodies.
This type of drug is not new, and many are currently approved to treat conditions such as cancer or rheumatoid arthritis. But some are being developed from scratch to boost the initial immune response for patients who are at risk of severe COVID-19 disease.
These experimental drugs may provide patients with a way to get ahead of the virus and help manage the strain on hospital intensive care services. But what are monoclonal antibodies?
Read more about this crucial tool in the fight against COVID-19 in Discovery's Edge, Mayo Clinic's research magazine offering insight into the process and progress of medical science at the world's largest group medical practice.
Make a gift now to help transform the future of health care today.
Michele Halyard, M.D., began her journey as a radiation oncologist at Mayo Clinic 36 years ago. Today, she is recognized as one of the most influential and impactful leaders in the movement toward health equity.
Lionel Kankeu Fonkoua, M.D., is an oncologist with Mayo Clinic Comprehensive Cancer Center who specializes in the treatment of gastrointestinal cancers. He is leading a clinical trial focused on the immigrant African and Asian communities of Minnesota with a high prevalence of one type of liver cancer.
Black people in America are about twice as likely to get Alzheimer's disease and other memory loss disorders. To better understand why, Floyd B. Willis, M.D., is helping the Mayo Clinic Alzheimer's Disease Research Center recruit participants into research studies.